Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in LEPR deficiency obesity
NL-OMON48914Phase 3Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Mar 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in leptin receptor deficiency comparing Setmelanotide then placebo withdrawal with Setmelanotide then continued setmelanotide (2 arms). Started Mar 2018; status: active, not recruiting.
02
Drugs
setmelanotide
03
Conditions
leptin receptor deficiency
Beyond the preview
Go deeper on NL-OMON48914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48914.